$0.01
9.89% yesterday
Nasdaq, Apr 04, 09:36 pm CET
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Evofem Biosciences, Inc. Stock price

$0.01
+0.00 14.12% 1M
+0.00 6.59% 6M
-0.00 2.02% YTD
-0.01 53.37% 1Y
-554.62 100.00% 3Y
-9,749.99 100.00% 5Y
-92,699.99 100.00% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.00 6.59%
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Key metrics

Market capitalization $1.03m
Enterprise Value $51.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.64
P/S ratio (TTM) P/S ratio 0.05
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 6.28%
Revenue (TTM) Revenue $19.36m
EBIT (operating result TTM) EBIT $-6.98m
Free Cash Flow (TTM) Free Cash Flow $-3.90m
Cash position $740.00k
EPS (TTM) EPS $-0.21
Short interest 11.01%
Show more

Is Evofem Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Evofem Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

Buy
100%

Financial data from Evofem Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
19 19
6% 6%
100%
- Direct Costs 4.57 4.57
45% 45%
24%
15 15
49% 49%
76%
- Selling and Administrative Expenses 19 19
18% 18%
99%
- Research and Development Expense 1.82 1.82
26% 26%
9%
-6.21 -6.21
61% 61%
-32%
- Depreciation and Amortization 0.77 0.77
57% 57%
4%
EBIT (Operating Income) EBIT -6.98 -6.98
61% 61%
-36%
Net Profit -8.86 -8.86
117% 117%
-46%

In millions USD.

Don't miss a Thing! We will send you all news about Evofem Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evofem Biosciences, Inc. Stock News

Neutral
PRNewsWire
10 days ago
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, ci...
Neutral
PRNewsWire
12 days ago
-- 2024 Net Sales Increased 6% to $19.4 Million  -- -- Total Operating Expense Reduced 27% from 2023 Levels,  Excluding Non-cash Amortization Expense  -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO , March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosci...
Neutral
GlobeNewsWire
16 days ago
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing ...
More Evofem Biosciences, Inc. News

Company Profile

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Saundra Pelletier
Employees 32
Founded 2007
Website www.evofem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today